Study the Levels of Il-12 and Alkaline Phosphatase in Brain Tumor Patients

Abstract

Current study aimed to accomplished by assessment levels of alkaline phosphatase and IL-12 levels in Iraqi patients with brain tumor. From November 2021 to February 2022, researchers at Al-Hussein Hospital in Karbala, Iraq, will investigate the prevalence of bacteremia and immunological markers in patients with brain tumors. 50 patients with brain tumors (27 males, 23 females) and 30 healthy people as control both patients and controls had blood drawn. Interleukin-12 (IL-12) levels estimated by ELISA technique. The findings indicated that the most vulnerable age group was 1–10-year-old, with a 26% infection rate compared to other age groups. Interleukin-12 levels in patients were lower than in healthy controls, while the level of Alkaline Phosphatase (188.22 U/L) was not substantially different from the healthy (187.76 U/L). Its conclude there's no significant difference in the level of alkaline phosphatase in patients than in healthy; so IL-12, It has been found the level has decreased in patients than in healthy persons.